ClinVar Miner

Submissions for variant NM_015450.3(POT1):c.898A>T (p.Asn300Tyr)

gnomAD frequency: 0.00001  dbSNP: rs774946163
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001219716 SCV001391666 uncertain significance Tumor predisposition syndrome 3 2022-04-01 criteria provided, single submitter clinical testing This sequence change replaces asparagine, which is neutral and polar, with tyrosine, which is neutral and polar, at codon 300 of the POT1 protein (p.Asn300Tyr). This variant is present in population databases (rs774946163, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with POT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 948458). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The tyrosine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
St. Jude Molecular Pathology, St. Jude Children's Research Hospital RCV001219716 SCV002584636 uncertain significance Tumor predisposition syndrome 3 2022-09-09 criteria provided, single submitter clinical testing The POT1 c.898A>T (p.Asn300Tyr) missense change has a maximum subpopulation frequency of 0.012% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. To our knowledge, this variant has not been reported in individuals with POT1-associated conditions. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance.
Ambry Genetics RCV003294058 SCV003995288 uncertain significance Hereditary cancer-predisposing syndrome 2023-05-30 criteria provided, single submitter clinical testing The p.N300Y variant (also known as c.898A>T), located in coding exon 7 of the POT1 gene, results from an A to T substitution at nucleotide position 898. The asparagine at codon 300 is replaced by tyrosine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.